[144] Ascendis Pharma A/S American SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Ascendis Pharma A/S (ASND) shows an intended sale of 3,036 American Depositary Shares through Merrill Lynch on NASDAQ with an aggregate market value of $588,814.29 and an approximate sale date of 08/27/2025. The shares were acquired on 09/21/2023 by warrant exercise from Ascendis Pharma A/S for cash. The filing also discloses a separate sale by Lotte Sonderbjerg of 25,000 ADS on 08/14/2025 generating gross proceeds of $4,789,998.27. The filer affirms no undisclosed material adverse information and includes the standard signature and attestation language.

Positive

• None.

Negative

• Insider selling activity disclosed: planned sale of 3,036 ADS valued at $588,814.29 and a recent sale of 25,000 ADS with gross proceeds of $4,789,998.27
• Limited context provided: filing does not state remaining holdings or relationship to issuer, restricting assessment of materiality

Insights

Securities Analyst

TL;DR: Insider-related disposal disclosed: small block (3,036 ADS) planned; recent larger sale (25,000 ADS) also reported.

The filing documents an intended sale of 3,036 ADS valued at $588,814.29 to be executed through Merrill Lynch on NASDAQ on or about 08/27/2025. These ADS were acquired via warrant exercise on 09/21/2023 and paid in cash. Separately, the record shows a prior sale of 25,000 ADS on 08/14/2025 with gross proceeds of $4,789,998.27 attributed to Lotte Sonderbjerg. For investors, these are factual disclosures of holder selling activity; the filing does not provide context on holdings remaining, ownership percentages, or reasons for sale.

Compliance & Governance Expert

TL;DR: Filing appears procedurally complete for Rule 144 notice with required acquisition and sale details included.

The Form 144 includes required elements: issuer class (ADS), broker name and address (Merrill Lynch 225 Liberty St Floor 37 New York NY 10281), number of shares, aggregate market value, acquisition date and method (warrant exercise on 09/21/2023), and a recent sale record (25,000 ADS on 08/14/2025). The notice also contains the standard attestation regarding material non-public information and criminal penalties for misstatement. The filing does not state the filer’s remaining holdings or relationship to the issuer, so further public filings would be needed to assess compliance context fully.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	3036	588814.29	60454589	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	09/21/2023	Warrant exercise	Ascendis Pharma A/S			3036	09/21/2023	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lotte Sonderbjerg TUBORG BOULEVARD 12 HELLERUP G7 00000	American Depositary Shares	08/14/2025	25000	4789998.27

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ASND disclose about the planned sale?

The form discloses an intended sale of 3,036 American Depositary Shares through Merrill Lynch on NASDAQ with aggregate market value $588,814.29 and approximate sale date 08/27/2025.

How were the 3,036 ADS acquired according to the filing?

The ADS were acquired on 09/21/2023 by warrant exercise from Ascendis Pharma A/S and paid for in cash.

Does the filing show any recent sales by the same person?

The filing lists a separate sale by Lotte Sonderbjerg of 25,000 ADS on 08/14/2025 with gross proceeds of $4,789,998.27.

Which broker and exchange are named in the notice?

The broker is Merrill Lynch, 225 Liberty St Floor 37, New York NY 10281 and the securities are to be sold on NASDAQ.

Does the filer attest to absence of undisclosed material information?

Yes. The notice contains the required representation that the person does not know any material adverse information about the issuer that has not been publicly disclosed.